Human Endogenous Retrovirus K(HML-2) Gag and Env specific T-cell responses are not detected in HTLV-I-infected subjects using standard peptide screening methods by Jones, R Brad  et al.
  Universidade de São Paulo
 
2013
 
Human Endogenous Retrovirus K(HML-2) Gag
and Env specific T-cell responses are not
detected in HTLV-I-infected subjects using
standard peptide screening methods
 
 
Journal of Negative Results in BioMedicine, London, v. 12, n. 3, p. 1-6, 2013
http://www.producao.usp.br/handle/BDPI/34781
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Clínica Médica - FM/MCM Artigos e Materiais de Revistas Científicas - FM/MIP
RESEARCH Open Access
Human Endogenous Retrovirus K(HML-2) Gag and
Env specific T-cell responses are not detected in
HTLV-I-infected subjects using standard peptide
screening methods
R Brad Jones1,2*, Fabio E Leal3,4, Aaron M Hasenkrug5, Aluisio C Segurado4, Douglas F Nixon5,
Mario A Ostrowski1,2 and Esper G Kallas3,4
Abstract
Background: An estimated 10–20 million individuals are infected with the retrovirus human T-cell leukemia virus
type 1 (HTLV-1). While the majority of these individuals remain asymptomatic, 0.3-4% develop a neurodegenerative
inflammatory disease, termed HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HAM/TSP
results in the progressive demyelination of the central nervous system and is a differential diagnosis of multiple
sclerosis (MS). The etiology of HAM/TSP is unclear, but evidence points to a role for CNS-inflitrating T-cells in
pathogenesis. Recently, the HTLV-1-Tax protein has been shown to induce transcription of the human endogenous
retrovirus (HERV) families W, H and K. Intriguingly, numerous studies have implicated these same HERV families in
MS, though this association remains controversial.
Results: Here, we explore the hypothesis that HTLV-1-infection results in the induction of HERV antigen expression
and the elicitation of HERV-specific T-cells responses which, in turn, may be reactive against neurons and other
tissues. PBMC from 15 HTLV-1-infected subjects, 5 of whom presented with HAM/TSP, were comprehensively
screened for T-cell responses to overlapping peptides spanning HERV-K(HML-2) Gag and Env. In addition, we
screened for responses to peptides derived from diverse HERV families, selected based on predicted binding to
predicted optimal epitopes. We observed a lack of responses to each of these peptide sets.
Conclusions: Thus, although the limited scope of our screening prevents us from conclusively disproving our
hypothesis, the current study does not provide data supporting a role for HERV-specific T-cell responses in HTLV-1
associated immunopathology.
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Background
Human T-cell leukemia virus type 1 (HTLV-1) is a del-
taretrovirus that has infected humans for thousands of
years. An estimated 10–20 million individuals worldwide
are infected with HTLV-1, the majority of whom will re-
main asymptomatic for life [1]. For a minority of
infected individuals, however, HTLV-1 infection is asso-
ciated with severe diseases, with 1-5% developing adult
T-cell leukemia/lymphoma [2] (ALT) and an additional
0.3-4% developing immune-mediated inflammatory dis-
ease involving the central nervous system, the eyes, the
lungs and/or the skeletal muscles [3]. Inflammation of the
central nervous system (CNS) in HTLV-1-infected sub-
jects results in progressive spasticity and muscle weakness
in lower extremities and is termed HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP) [4].
The etiology of HAM/TSP is poorly understood, however
it is associated with higher HTLV-1 proviral loads, a
higher frequency of HTLV-1-specific CD8+ T-cells and
greater production of IFN-γ and TNF-α than that
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observed in asymptomatic HTLV-1-infected subjects, sug-
gesting the involvement of cellular immune responses in
the pathogenesis [5-8]. As there is no evidence that
HTLV-1 infects astrocytes, microglia or neuronal cells,
it is unlikely that the damage incurred by these cell
populations is mediated by direct recognition of HTLV-
1 antigens presented on these cells by HTLV-1-specific
CD8+ T-cells. Two potential mechanisms have been
proposed to explain how HTLV-1-specific CD8+ T-cells
could mediate damage to non-HTLV-1-infected cells.
Firstly, this damage could occur simply as a bystander
effect of HTLV-1-specific CD8+ T-cells recognizing the
HTLV-1-infected T-cells that have been shown to accu-
mulate in the CNS. Secondly, it has been suggested that
there may be cross-reactivity of HTLV-1-specific CD8+
T-cells with self antigens expressed in neurons [9].
Here, we present and explore a third possibility, that
HTLV-1-infection may elicit human endogenous retro-
virus (HERV) specific CD8+ T-cell responses which, in
turn, may be reactive against neurons and other tissues
where HERV antigens may be expressed.
Human endogenous retroviruses, the DNA remnants
of ancient infectious retroviruses, comprise approxi-
mately 8% of the human genome. This complement of
HERVs is diverse, with all three major branches of the
retroviral tree represented: gamma-epsilon, spuma and
delta-lenti-alpha-beta retroviruses [10]. While the vast
majority of HERV insertions do not contain intact open
reading frames (ORFs), a recent study has illustrated the
potential for even short, disrupted ORFs to serve as a
source of immunologically relevant antigens, by mapping
the epitope specificity of a renal cell carcinoma reactive
CD8+ T-cell to a HERV-E-derived peptide [11]. As a
gross generalization, HERV antigens are not thought to
be expressed in healthy tissues, but rather are associated
with transformed cell lines and disease states. We have
previously presented the hypothesis that HIV-1 infection
would result in the induction of HERV expression, either
through rescue of HERV function by HIV-1, for ex-
ample, nuclear export of unspliced HERV RNA by HIV-
1 Rev, or through the degradation of host restriction
factors which may normally keep HERV expression in
check [12]. Indirect support for this hypothesis is
provided by our observation that T-cell responses to
peptides derived from diverse HERV families can be
detected in HIV-1-infected, but not uninfected, subjects
[12-14]. We have since focused in on the HERV-K
(HML-2) lineage of young and relatively intact endogen-
ous retroviruses, and determined that HIV-1 infection
results in the induction of Gag and Env protein expres-
sion. A HERV-K(HML-2)-Env-specific CD8+ T-cell clone,
isolated from an HIV-1-infected subject, specifically
responded to and eliminated cells infected with diverse
isolates of HIV-1, HIV-2 and SIV [15]. The establishment
of this precedent for induction of HERV expression by
an exogenous retroviruses led us to consider whether
HTLV-1, as a second human retrovirus, may also drive the
expression of HERVs. This idea draws support from a very
recent study which demonstrated that the HTLV-1-Tax
protein drives transcription from the long-terminal
repeats (LTR) of HERV-W8, HERV-H and HERV-K
[16]. In the current study we sought to obtain indirect
evidence for the in vivo expression of HERV antigens,
by screening PBMC from HTLV-1-infected subjects for
T-cell responses to HERV-derived peptides, with a
particular focus on the HERV-K(HML-2) lineage.
In addition to providing evidence for the HTLV-
1-induced expression of HERVs, the detection of
HERV-specific T-cell responses in HTLV-1-infected
subjects would open a line of inquiry into determining
whether such responses may contribute to the patho-
genesis of HAM/TSP. It is intriguing to note, given
the similarities in clinical presentation and pathogen-
esis of HAM/TSP and multiple sclerosis (MS), that
numerous studies have associated HERV polymorph-
isms or expression levels with MS (reviewed in [17]).
Specifically, HERV-H, HERV-W, and HERV-K have
been associated with MS, the same families shown to
be induced at the transcriptional level by HTLV-
1-Tax. We posited that HTLV-1 infection would result
in the expression of HERV antigens and the induction
of HERV-specific T-cell responses, which would, in turn,
be reactive against neurons and other tissues which may
express low levels of HERV antigens, resulting in the path-
ologies of HAM/TSP. Consistent with this, we have
recently performed a comprehensive screening of human
tissues for HERV-K(HML-2)-Gag expression and detected
this protein in the central nervous system (neurons, pur-
kinje cells and occasionally ependymal cells), as well as
in the endocrine pancreas (few cells in the β-islets
of Langerhans) and in the exocrine pancreas (ductal
epithelial cells) (Sacha et al. Submitted).
Results and discussion
To test this hypothesis, we obtained peripheral blood
mononuclear cells (PBMC) from 15 HTLV-1-infected
subjects from Sao Paulo, Brazil, and from 8 age/sex
matched uninfected subjects from the same geographical
area. The HTLV-1-infected subjects comprised 9 indivi-
duals who were asymptomatic, 5 with HAM/TSP and 1
subject who we define as pre-ATL. In the latter subject,
significant immunophenotype alterations were present at
the time of sample collection, but the criteria for an
ATL diagnosis were not present. Six months later, this
patient was diagnosed with the lymphomatous variant of
ATL (Table 1). These PBMC were screened for T-cell
responses by IFN-γ ELISPOT. The primary objective of
these experiments was to comprehensively screen for
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responses to HERV-K(HML-2) Gag and Env using over-
lapping peptide pools spanning these antigens. We did
also screen these subjects for responses to peptides
derived from diverse HERV families selected based on
predicted binding to common MHC-I alleles, many of
which have previously been demonstrated to be immu-
noreactive HIV-1-infected subjects [12-14]. However, as
we had no prior knowledge of the HLA-types of subjects
in our cohort, the latter screening was performed with-
out consideration of whether subjects possessed the ne-
cessary restricting alleles, imposing limitations on our
ability to draw conclusions from these data. Peptides
tested were thus: i) 15mer peptides, overlapping by 11
amino acids, spanning HERV-K(HML-2) Gag and Env –
tested in pools of 10 peptides each at 25 μg/ml/peptide
ii) 29 shorter peptides (9–13 amino acids) derived from
HERV-K(HML-2), HERV-L, HERV-H and HERV-W
(Table 2) – tested in pools of 7 peptides each at
10 μg/ml/peptide. These peptides have been previously
described [12-14], and were selected based on predicted
binding to the MHC-I alleles A02, B58, B07 or B35 iii)
the immunodominant HLA-A02-restricted Tax 11–19
peptide tested at 10 μg/ml iv) a pool of CMV, EBV and
influenza derived peptides (CEF pool) as a positive
control tested at 2.5 μg/ml/peptide v) Staphylococcus en-
terotoxin B (SEB) tested at 2.5 μg/ml. ELISPOTS were
performed as previously described [13], except that
stimulation periods were limited to 6 hours. Longer
periods of in vitro culture of PBMC derived from
HTLV-1-infected subjects resulted in very high levels of
spontaneous IFN-γ production, as has been previously
reported [18].
We observed a total of 12 HERV-specific responses
in HTLV-1-infected individuals which passed our pre-
established criteria of > 50 sfu/106 PBMC after back-
ground subtraction and > 3x background versus 3
HERV-specific responses in uninfected subjects. These
responses were, however, of borderline magnitude and
replicates between duplicate wells were poor. We sought
to repeat these responses with new aliquots of cells from
the same patient time-points using the same peptide
Table 1 Clinical data
Healthy donors Gender Age Proviral load copies/ 1000 cells
HD001 F 39 NA
HD002 F 30 NA
HD003 M 21 NA
HD004 M 31 NA
HD005 F 60 NA
HD006 M 51 NA
HD007 M 38 NA
HD008 F 45 NA
Asymptomatic
401 F 56 <1
403 F 55 ND
405 F 23 15
409 M 20 1
416 M 49 1162
419 F 34 72
424 M 46 106
425 M 29 43
426 F 51 101
HAM/TSP
404 M 45 4
407 M 61 357
412 F 55 18
415 F 27 444
420 M 64 12
Pre ATL
413 F 62 3650
Table 2 HERV-Opt peptides – selected on basis of
predicted binding to common MHC-I alleles
Antigen Sequence
HERV-K-Pol KLIDCYTFL
HERV-K-Gag KLFQIIEQF
HERV-K-Gag YPQPPTRRL
HERV-K-Pol FAFTIPAI
HERV-K-Pol FEGLVDTGAD
HERV-K-Pol VPLTKEQVR
HERV-K-Pol IPTGVYPGL
HERV-L LQDIILVHY
HERV-L VVIQITSPFNSPKW
HERV-L SQGYINSPAL
HERV-L QINTSPGTW
HERV-L KAHKKQFAFSW
HERV-L RSWRMTVDYCKL
HERV-L IPVHKAHKKQ
HERV-K-Gag QNIIPLTVW
HERV-H LDLLTAEKGGLCI
HERV-K-Gag FLQFKTWWI
HERV-K-Pol GIPYNSQGQ
HERV-K-Gag KSSLSPSQF
HERV-K-Pol VSIIALNQW
HERV-K-Gag RLIPYDWEI
HERV-W DSIEGQLILK
HERV-C TLEPIPPGE
HERV-L KIRLPPGYF
HERV-L ILVHYIDDI
HERV-L AAIDLANAF
HERV-L PMVSTPATL
HERV-L SSGLMLMEF
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pools and, in parallel, to deconvolute responses to pools
by testing individual peptides. In these follow-up experi-
ments we observed that none of these responses were
reproducible. The incidence of these false positive
responses was related to ‘noisier’ ELISPOTs than those
typically observed using PBMC from HTLV-1-uninfected
subjects. Although we sought to minimize the impact of
spontaneous IFN-γ production on the assay by reducing
stimulation periods to 6 hours, we observed higher levels
of background in ELISPOTs performed on HTLV-
1-infected subjects than in uninfected controls. Despite
this background, we observed clear and reproducible
responses to the HLA-A02-restricted Tax peptide in 6
HTLV-1 subjects, and an absence of this response in unin-
fected subjects. Responses to CEF pool were detected in
the majority of both HTLV-1-infected and uninfected
subjects.
We next summed the background-subtracted responses
to: HERV-K(HML-2)-Env, HERV-K(HML-2)-Gag and
predicted optimal HERV peptides (HERV-Opt). In screens
performed on non-HTLV-1-infected subjects ELISPOT
results with negative values after background subtraction
are atypical and generally reported as zero. In the present
case, however, the variability caused by spontaneous cyto-
kine production, and summed over multiple peptide pools
in the cases of HERV-K(HML-2)-Gag and Env (17 and 18
pools respectively), manifested as cumulative totals which
spanned a range from substantially more than to less than
zero. As zeroing these negative values would give the false
impression of positive responses in HTLV-1-infected sub-
jects (instead of just cumulative noise) these data are pre-
sented as is. We observed a lack of statistically significant
differences between the magnitudes of responses detected
in HTLV-1-infected versus uninfected subjects for each of
the peptide sets tested (Figure 1). Notably, however, we
did observe a trend towards the detection of responses to
the HLA-A02-restricted Tax peptide in HTLV-1-infected
subjects (p=0.135). The failure of this response to reach
significance is likely tied to the fact that subjects were
tested without a prior knowledge of their HLA types.
Thus, only a minority (approximately 40%) of subjects
would be expected to have the capacity to present this
particular peptide. A lack of statistically significant differ-
ences in magnitudes of responses to HERV, Tax or CEF
peptides were also observed when we broke the HTLV-1-
infected subjects into asymptomatic versus HAM/TSP
groups (data not shown). We did, however, observe a posi-
tive correlation between the magnitude of responses to
the HLA-A02-restricted Tax peptide and HTLV-1 proviral
load (considering all subjects, not just responders)
(R=0.785, p=0.002, Table 3). This is in agreement with
observations from two previous reports [19,20]. We did
not observe any such correlation with magnitudes of
responses to HERV-K(HML-2) Env or Gag, to the
optimized HERV peptide pool or to CEF (Table 3). Thus
the data are indicative of a lack of detectable T-cell
responses to the HERV-derived peptides considered in the
present study.
Conclusions
The current study does not provide any data to support
the hypothesis that the induction of HERV expression
and HERV-specific T-cell responses in HTLV-1-infected
subjects may play a role in the pathogenesis of HAM/
TSP. This may indicate that, in contrast to HIV-1,
HTLV-1 does not induce HERV expression. We have re-
cently demonstrated that the HIV-1-Vif protein is neces-
sary for the induction of HERV-K(HML-2) expression
[15], thus the lack of a Vif equivalent in HTLV-1 may at
least partially underlie this difference. There are a num-
ber of important caveats, however, which prevent the
current study from comprehensively ruling out a role for
HERVs in HTLV-1 pathogenesis. Firstly, the HERV-
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Figure 1 Summary ELISPOT data. PBMC from HTLV-1-infected and
uninfected subjects were screened with the indicated peptides in
IFN-γ ELISPOT assays. In the cases of HERV-K-Env, HERV-K-Gag and
HERV-Opt the mean background (0.5% DMSO) subtracted responses
to individual peptide pools (18 pools for Env, 17 pools for Gag, 4
pools for Opt) were summed to give a total response. Responses are
expressed as spot forming units (SFU) per million PBMC. P values
were calculated using Student’s T-test.
Table 3 Correlations between magnitudes of responses
and HTLV-I proviral loads
Peptides R value P value
HERV-K-Env 0.141 0.647
HERV-K-Gag 0.199 0.515
HERV-Opt 0.098 0.751
CEF Pool 0.023 0.940
Tax Peptide 0.785 0.002
SEB 0.158 0.606
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derived peptides tested in the current study only repre-
sent a small fraction of the total HERV antigens encoded
in the human genome. In particular, HERV-H and HERV-
W, which were shown to be transcriptionally induced to
the greatest level by Tax in a recent study [16], were only
represented by one peptide each (this study was published
after our experiments were completed). Secondly, the
HERV peptides, predicted to be optimal binders for either
HLA-A02, B07, B58 or B35, were tested without a prior
knowledge of the HLA-types of the test subjects in this
cohort. HLA-A02 is common enough (~40% prevalence
in this cohort) that responses to immunodominant HLA-
A02-restricted HERV-derived peptides would likely have
been detected in this cohort, as is evidenced by our detec-
tion of responses to the HLA-A02-restricted Tax peptide.
However, the detection of responses restricted by the less
common B07, B58, or B35 alleles was unlikely. Indeed,
these were tested as an adjunct to the primary objective of
the current study, which was to comprehensively screen
for responses to HERV-K(HML-2) Gag and Env. Import-
antly, in our previous studies measuring responses to
these predicted optimal epitopes in HIV-1-infected
subjects, these peptides were tested against a cohort of
subjects selected on the basis of having one or more of
these restricting alleles. In the current manuscript, we do
comprehensively screen for T-cell responses to HERV-K
(HML-2) Gag and Env using overlapping 15mer peptides.
This approach is not reliant upon prior knowledge of a
subject’s HLA-type, and yet a lack of T-cell responses
was still observed. When we have previously screened
HIV-1-infected subjects with these same peptides we
observed only infrequent responses, with 3 responses
detected in the 27 subjects who were screened [21].
Thirdly, the peptides used in the current study represent
only a small fraction of the potential HERV antigens
encoded by 8% of our genome. The current study is best
interpreted as a starting point, effectively ruling out the
presence of responses to HERV-K(HML-2) Gag and Env
that are detectable using 15mer peptide screens. The
recent demonstration that HERV-H and HERV-W are
most potently induced at the transcriptional level by
HTLV-1-Tax, with a lesser induction of HERV-K, suggests
that future studies should focus on screening for T-cell
responses to these HERV families. Finally, while we have
focused exclusively on T-cell responses as potential
mediators, there are also other potential mechanisms by
which putative HTLV-1-mediated HERV induction could
result in pathogenesis – for example, through antibody
mediated immunopathology or through direct effects of
HERV gene products on the affected tissue (toxicities of
Env proteins for example). Although limited by the
caveats given above, the current study argues against a
role for an involvement of HERVs in the immunopatho-
genesis of HTLV-I infection.
Methods
Samples were collected under an IRB approved protocol.
PBMC were isolated through Ficoll gradient enrichment
and cryopreserved. ELISPOT assays were performed as
previously described [21], but with a 6 hour, rather than
overnight, stimulation period. Peptides were tested as
follows: 15mer peptides, overlapping by 11 amino acids,
spanning HERV-K(HML-2) Gag and Env – tested in pools
of 10 peptides each at 25 μg/ml/peptide ii) 29 shorter pep-
tides (9–13 amino acids) derived from HERV-K(HML-2),
HERV-L, HERV-H and HERV-W (Table 2) – tested in
pools of 7 peptides each at 10 μg/ml/peptide iii) the
immunodominant HLA-A02-restricted Tax 11–19 peptide
tested at 10 μg/ml iv) a pool of CMV, EBV and influenza
derived peptides (CEF pool) tested at 2.5 μg/ml/peptide.
Staphylococcus enterotoxin B (SEB) was used at 2.5 μg/ml.
A response was considered to be positive if it passed both
the criteria of: i) > 50 sfu/million PBMC after background
subtraction and ii) > 3x background. Statistics were per-
formed using Prism Graphpad 2.0 software.
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